Table 1.
Demographic and clinical characteristics of patients with COVID-19 on admission
| Total (n = 150) | Non-survivor (n = 31) | Survivor (n = 119) | P value | |
|---|---|---|---|---|
| Demographics | ||||
| Age, y | 52 (39.5-66.5) | 73 (62-79) | 48 (37-57) | <0.001 |
| Sex, n (%) | ||||
| Male | 69 (46.0%) | 19 (61.3%) | 50 (42.0%) | 0.055 |
| Female | 81 (54.0%) | 12 (38.7%) | 69 (58.0%) | |
| Underlying diseases, n (%) | 54 (36.0%) | 23 (74.2%) | 31 (26.1%) | <0.001 |
| Hypertension | 25 (16.7%) | 14 (45.2%) | 11 (9.2%) | <0.001 |
| Diabetes | 17 (11.3%) | 11 (35.5%) | 6 (5.0%) | <0.001 |
| Cardiovascular disease | 12 (8.0%) | 9 (29.0%) | 3 (2.5%) | <0.001 |
| Cerebrovascular diseases | 10 (6.7%) | 7 (22.6%) | 3 (2.5%) | <0.001 |
| Chronic respiratory disease | 6 (4.0%) | 3 (9.7%) | 3(2.5%) | 0.195 |
| Chronic kidney disease | 2 (1.3%) | 2 (6.5%) | 0 (0.0%) | 0.042 |
| Malignancy | 3 (2.0%) | 2 (6.5%) | 1 (0.8%) | 0.109 |
| Others | 13 (8.7%) | 3 (9.8%) | 10 (8.4%) | 1.000 |
| Current smoker, n (%) | 12 (8.0%) | 2 (6.5%) | 10 (8.4%) | 1.000 |
| Exposure history, n (%) | 50 (33.3%) | 8 (25.8%) | 42 (35.3%) | 0.318 |
| Clinical characteristics | ||||
| Symptom, n (%) | ||||
| Fever (temperature ≥37·3°C) | 115 (76.7%) | 26 (83.9%) | 89 (74.8%) | 0.287 |
| Cough | 104 (69.3%) | 22 (71.0%) | 82 (68.9%) | 0.825 |
| Sputum production | 49 (32.7%) | 11 (35.5%) | 38 (31.9%) | 0.707 |
| Chest discomfort | 53 (35.3%) | 15 (48.4%) | 38 (31.9%) | 0.088 |
| Dyspnea | 21 (14.0%) | 11 (35.5%) | 10 (8.4%) | <0.001 |
| Fatigue | 86 (57.3%) | 27 (87.1%) | 59 (49.6%) | <0.001 |
| Myalgia | 42 (28.0%) | 6 (19.4%) | 36 (30.3%) | 0.229 |
| Diarrhea | 12 (8.0%) | 2 (6.5%) | 10 (8.4%) | 1.000 |
| Respiratory rate, breaths/min | 20 (19-21) | 21 (20-25) | 20 (19-21) | 0.016 |
| Pulse, beats/min | 80 (75-88) | 86 (74-106) | 80 (75-86) | 0.134 |
| Mean arterial pressure, mmHg | 93 (89-98) | 97 (90-108) | 93 (88-97) | 0.048 |
| Disease severity status, n (%) | ||||
| General | 101 (67.3%) | 2 (6.5%) | 99 (83.2%) | |
| Severe | 40 (26.7%) | 20 (64.5%) | 20 (16.8%) | <0.001 |
| Critical | 9 (6.0%) | 9 (29.0%) | 0 (0.0%) | |
| CURB-65 score, n (%) | ||||
| 0-1 | 126 (84.0%) | 16 (51.6%) | 110 (92.4%) | |
| 2-3 | 22 (14.7%) | 13 (41.9%) | 9 (7.6%) | <0.001 |
| 4-5 | 2 (1.3%) | 2 (6.5%) | 0 (0.0%) | |
| PSI score, n (%) | ||||
| I | 61 (40.7%) | 2 (6.5%) | 59 (49.6%) | |
| II-III | 65 (43.3%) | 10 (32.2%) | 55 (46.2%) | <0.001 |
| IV-V | 24 (16.0%) | 19 (61.3%) | 5 (4.2%) | |
| SOFA score | 1 (0-3) | 4 (3-7) | 1 (0-1) | <0.001 |
| APACHE||score | 4 (2-7.3) | 10 (7-19) | 4 (2-6) | <0.001 |
| Time from exposure to illness onset, days* | 5.5 (4.8-10) | 6 (4.3-12.3) | 5.5 (4.5-10) | 0.975 |
| Time from illness onset to hospital admission, days | 7 (5-10) | 7 (6-10) | 7 (5-10) | 0.286 |
Abbreviations: PSI, Pneumonia Severity Index; SOFA, Sequential Organ Failure Assessment; APACHE||, Acute Physiology and Chronic Health Evaluation.
*
Data available for 30 patients, including 4 non-survivors and 26 survivors.